INTRODUCTION
Infantile hemangioma (IH) is the most frequent benign tumor in the pediatric population, with an incidence of 5% to 10%. 1 These tumors usually do not present with systemic involvement. In cases of extensive and segmental IH, especially on the face, scalp, and cervical region, a clinical and imaging workup is recommended to detect the changes that are described in PHACE syndrome. 2 The most remarkable feature of PHACE syndrome is IH, but abnormalities in the brain, aortic, thoracic, and cervical arteries, which are not obvious on clinical examination, have considerable potential for morbidity. 3, 4 females more frequently (9:1). Infantile hemangioma (most cases), cerebrovascular (83% to 91%) and cardiac (41% to 67%) changes are among its most common manifestations.
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PATHOGENESIS
The pathogenesis of PHACE syndrome is unknown. It has been postulated to result from defective embryogenesis between weeks 3 and 12 of gestation, before or during vasculogenesis, because certain malformations and IH can affect the same side of the body.
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There is no evidence of genetic abnormalities that contribute to the development of PHACE syndrome.
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DIAGNOSTIC CRITERIA
In 2009, a group of various specialties (dermatology, neurology, oncology, genetics, cardiology, and ophthalmology) established criteria for the diagnosis of PHACE syndrome, stratifying it into 2 categories:
1. PHACE syndrome, defined by the presence of segmental IH larger than 5cm on the face, scalp, or cervical region, associated with 1 major criterion or 2 minor criteria.
2. Possible PHACE syndrome, defined by the presence of IH and 1 minor criterion.
Major and minor criteria have been determined, based on the vascular and structural involvement of the brain, cardiovascular system, eye, and midline (Chart 1). 8 In 2016, new recommendations for the diagnosis and follow-up of patients with PHACE syndrome were published by a multidisciplinary group, comprising neuroradiology, neurosurgery, neurology, cardiology, cardiothoracic surgery, dermatology, otorhinolaryngology, hematology-oncology, and plastic surgery. In addition to medical experience and a literature review of the extracutaneous involvement, prevalence, progression and morbidity of PHACE syndrome, follow-up and family care were included.
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CUTANEOUS INVOLVEMENT
At birth, IH can be absent or present as a precursor lesion that is represented by a pale or slightly erythematous or telangiectatic area. However, nearly all IHs are already visible at the end of the first month of life. Regarding its progression, 3 phases have been described: proliferation (with increased growth in the first 5 months of life), stabilization, and spontaneous involution (lasting for years). 10, 13 IHs that are associated with PHACE syndrome tend to be large (>5cm in diameter) or segmental-a term that has been proposed to describe the morphology of the hemangioma that affects one region and does not arise from a focal point. These IHs can present as telangiectasias, solitary lesions, confluent plaques, small papules that assume a specific distribution, and tumors with deeper involvement. 14 have also been described in PHACE syndrome. 15 Large IHs on the infraorbital region that cause proptosis can be associated with the typical arterial anomalies in PHACE syndrome ( Figure 5 ). 16 Further, in the definition of possible PHACE syndrome, a small, nonsegmental IH or even the absence of cutaneous hemangiomas can be observed. (Figure 7 ). When the lesions are unilateral, the vascular changes and cutaneous IH tend to be on the same side.
In most cases, the cerebral lesions do not progress, but the associated signs and symptoms of neuropsychomotor developmental delay, seizures, and headaches should be monitored. Pituitary structural abnormalities or symptoms that are suggestive of endocrine diseases should be examined in these cases. 21 Because structural and vascular brain changes can lead to neurological sequelae, such as seizures and developmental delays, Tangtiphaiboontana et al. followed the neurological development of 29 children with PHACE syndrome aged over 1 year. In 20 children, delays in speech and changes in gross motor development were seen. 22 However, there are few studies on the morbidity and neurological outcome in these patients. Neurological follow-up is important in determining the prognosis and appropriate therapeutic intervention.
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CARDIAC INVOLVEMENT
The prevalence of congenital cardiac diseases in patients with PHACE syndrome is 41% to 67%, being coarctation of the aorta responsible for 19-30% of these cases. 24 Approximately 50% of patients with cardiac involvement have an aberrant origin of the subclavian artery, with or without a vascular ring. 25 The most frequent changes to the aortic arch arise in the transverse and descendent
portions. An obstruction usually occurs in the long segment instead of the juxtaductal portion, which is the most affected area in patients with malformations that are unrelated to PHACE syndrome. This obstruction is characterized by a narrowing or interruption, with subsequent aneurysmatic dilatation of the adjacent segments.
In patients with PHACE syndrome, 37% of cases with aortic arch anomalies will need surgical intervention. Nonsurgical cases should be followed with an annual echocardiogram due to the possibility of lesion progression. Headaches are more frequent and intense and begin at an early age. In these cases, a neurological assessment and an investigation of vasculopathy and cerebral ischemia should be performed using imaging tests, even in the absence of cerebrovascular changes on the initial MRI.
Auditory deficiency and speech delay are common findings.
Delayed language can be due to an auditory deficit from neurosensory involvement when the IH affects cranial nerve VIII (vestibulocochlear). In these cases, the diagnosis should be made as early as possible to ensure therapeutic success and avoid sequelae. All patients with PHACE syndrome should be assessed in the neonatal period and, if they have a high risk for auditory deficiency, undergo an annual audiological evaluation. 26 Certain patients with PHACE syndrome can present with dysphagia, feeding difficulties, and speech delays. 27 These changes are usually observed in patients with posterior fossa malformations; lip, oropharyngeal, and airway IHs; and previous cardiac surgery. Dysphagia can be secondary to the location of the IH (lips, oral cavity, and pharynx) or to motor coordination. Speech delays that are detected early should be followed by an otorhinolaryngologist; an approach with timely speech therapy will determine its progress. 3, 26 Endocrine abnormalities have been described in PHACE syndrome, such as thyroid dysfunction, hypopituitarism with growth hormone deficiency, and adrenal insufficiency. 28 Hypothyroidism can be caused by changes in the hypothalamus, pituitary gland, or thyroid, which can be ectopic or malformed. 29 Neonatal hypoglycemia can be a sign of hypopituitarism and warrants endocrine screening. Other effects of pituitary dysfunction include hypogonadotropic hypogonadism, which manifests as delayed puberty and adrenal insufficiency. 28 Dental abnormalities, including enamel hypoplasia, which increases the risk of cavities, have also been described. They are more frequent when the hemangioma is located in the oral cavity, and dental follow-up is recommended starting in the first year of life. There is no consensus regarding the frequency with which imaging should be performed. In certain institutions, especially for high-risk cases, the tests are performed every 3 months, whereas others conduct them annually. Each case must be considered individually according to its abnormalities and associated symptoms.
The indications for such tests must be carefully evaluated due to exposure to the anesthetic and contrast agent. Several services have adopted the restraining technique to avoid sedation and anesthesia.
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INFANTILE HEMANGIOMA TREATMENT
Propranolol is the preferred medication for IH when systemic treatment is indicated. 33 The safe use of propranolol in patients with PHACE syndrome is based on a careful examination of potential extracutaneous anomalies that are associated with the IH, and the therapeutic choice depends on the recommendations of a multidisciplinary team.
There are several controversies regarding the use of propranolol in PHACE syndrome patients who have arterial disease due to the risk of CVA. However, the few CVA cases in the literature had severe arteriopathies. 8, 19 In PHACE syndrome, propranolol use should be consid- drome who were treated with oral propranolol, 7 of whom were at high risk for CVA, based on the MRA, and in whom the syndrome was associated with cardiovascular abnormalities. Of the patients who were being followed, one presented with hemiparesis; in this case, treatment with propranolol was maintained, and there was recovery from motor deficits. The authors concluded that the risk for CVA in these patients is related to several factors, including arterial stenosis, abnormalities of the circle of Willis, the degree of collateral circulation, and the coexistence of cardiac and aortic arch anomalies that can lead to thromboembolic events. 20 Although the resolution of IH is well documented during treatment with oral propranolol, several authors have reported the possibility of recurrence and tumor growth on discontinuation. 34 We believe that in these cases, the medication was halted prematurely-in the proliferative phase and especially for deep and segmental
IHs. We conclude that the treatment duration will depend on the intrinsic features and clinical progression of each IH. Thus, the treatment should be discontinued when there is no further reduction in the lesion while on the medication. 35, 36 It is necessary to follow the patient after he stops taking propranolol, and in cases of recurrence, the medication can be restarted.
OUTCOME AND PROGNOSIS
Recent studies have detailed the features of PHACE syndrome, but the long-term outcomes for such patients are poorly described. Brain and cervical vascular anomalies are observed in most cases, but there are no reports on the clinical outcomes of these changes after propranolol use.
The most common extracutaneous involvement is structural and vascular in the brain. Thus, neurological and cognitive impairments are potential causes of morbidity in these patients. 2 A multidisciplinary assessment that identifies possible CNS, cardiac, ocular, hormonal, auditory, language, and swallowing abnormalities in a timely manner allows effective interventions to be implemented to prevent future complications. q
